The baculoviral inhibitors of apoptosis play a significant role in infectivity and viral host-range, which make them potential candidates for the engineering and improvement of baculovirus insecticidal. The iap3 gene ...The baculoviral inhibitors of apoptosis play a significant role in infectivity and viral host-range, which make them potential candidates for the engineering and improvement of baculovirus insecticidal. The iap3 gene of Spodoptera exigua nucleopolyhedrovirus （SeMNPV）, amplified by PCR, was 939 bp encoding IAP3. The PCR product was cloned into EcoR I/Barn H I of the plasmid pEGFP-C1. GFP was fused to the N-terminaus of IAP3 to study distribution in HEK293. It was observed that the plasmid expressing IAP3 significantly inhibited apoptosis induced by cisplatin in HEK293 cells. We conclude that the IAP3 of SeMNPV is functional in mammalian cells.展开更多
The efficacy of many cancer treatments is due to their ability to induce apoptosis. DR5 can activate apoptosis pathway after binding with its natural ligand, tumour necrosis factor-related apoptosis-inducing ligand （...The efficacy of many cancer treatments is due to their ability to induce apoptosis. DR5 can activate apoptosis pathway after binding with its natural ligand, tumour necrosis factor-related apoptosis-inducing ligand （TRAIL/ Apo2L）. Both TRAIL and agonistic anti-DR5 monoclonal antibody are currently being explored for cancer therapy. The mechanisms of cytotoxicity of our previously prepared monoclonal antibody A6 against DR5 were investigated here. A6 could cause viability loss of Jurkat cells in both time- and dose-dependent manner which could be attributed to the activation of apoptosis pathway. Caspases 3, 8 and 9 were activated in Jurkat cells and the caspase specific inhibitors, such as broad caspases inhibitor Z-VAD-FMK, caspase 8 specific inhibitor Z-IETDFMK and caspase 9 specific inhibitor Z-LEHD-FMK could recover the viability loss caused by A6. The function and molecular mechanism of TRAIL-mediated apoptosis were also investigated and compared with those of A6. Although A6 and TRAIL recognize a different epitope, they could induce a similar reaction in Jurkat cells.展开更多
Gout is a disease that has been pestering humankind for centuries.Hence,gout therapeutics has always been a field of ongoing research.Beginning from colchicine,which was the first drug to come into use,to the latest i...Gout is a disease that has been pestering humankind for centuries.Hence,gout therapeutics has always been a field of ongoing research.Beginning from colchicine,which was the first drug to come into use,to the latest inflammasome inhibitors and monoclonal antibodies,therapies for gout have evolved remarkably over the years.Although gout-related research came to a standstill in the late 20th century,the 21st century witnessed a renaissance in gout therapeutics with the advent of new xanthine oxidase inhibitors.Our present armamentarium against gout includes drugs that exploit the newfound knowledge about the various mechanisms involved in the pathogenesis of gout as well as drugs used in other conditions,which are effective in gout as well.Many more drugs that promise better management of gout in the future are in the pipeline.展开更多
文摘The baculoviral inhibitors of apoptosis play a significant role in infectivity and viral host-range, which make them potential candidates for the engineering and improvement of baculovirus insecticidal. The iap3 gene of Spodoptera exigua nucleopolyhedrovirus （SeMNPV）, amplified by PCR, was 939 bp encoding IAP3. The PCR product was cloned into EcoR I/Barn H I of the plasmid pEGFP-C1. GFP was fused to the N-terminaus of IAP3 to study distribution in HEK293. It was observed that the plasmid expressing IAP3 significantly inhibited apoptosis induced by cisplatin in HEK293 cells. We conclude that the IAP3 of SeMNPV is functional in mammalian cells.
文摘The efficacy of many cancer treatments is due to their ability to induce apoptosis. DR5 can activate apoptosis pathway after binding with its natural ligand, tumour necrosis factor-related apoptosis-inducing ligand （TRAIL/ Apo2L）. Both TRAIL and agonistic anti-DR5 monoclonal antibody are currently being explored for cancer therapy. The mechanisms of cytotoxicity of our previously prepared monoclonal antibody A6 against DR5 were investigated here. A6 could cause viability loss of Jurkat cells in both time- and dose-dependent manner which could be attributed to the activation of apoptosis pathway. Caspases 3, 8 and 9 were activated in Jurkat cells and the caspase specific inhibitors, such as broad caspases inhibitor Z-VAD-FMK, caspase 8 specific inhibitor Z-IETDFMK and caspase 9 specific inhibitor Z-LEHD-FMK could recover the viability loss caused by A6. The function and molecular mechanism of TRAIL-mediated apoptosis were also investigated and compared with those of A6. Although A6 and TRAIL recognize a different epitope, they could induce a similar reaction in Jurkat cells.
文摘Gout is a disease that has been pestering humankind for centuries.Hence,gout therapeutics has always been a field of ongoing research.Beginning from colchicine,which was the first drug to come into use,to the latest inflammasome inhibitors and monoclonal antibodies,therapies for gout have evolved remarkably over the years.Although gout-related research came to a standstill in the late 20th century,the 21st century witnessed a renaissance in gout therapeutics with the advent of new xanthine oxidase inhibitors.Our present armamentarium against gout includes drugs that exploit the newfound knowledge about the various mechanisms involved in the pathogenesis of gout as well as drugs used in other conditions,which are effective in gout as well.Many more drugs that promise better management of gout in the future are in the pipeline.
